JP6928450B2 - エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 - Google Patents

エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP6928450B2
JP6928450B2 JP2016525428A JP2016525428A JP6928450B2 JP 6928450 B2 JP6928450 B2 JP 6928450B2 JP 2016525428 A JP2016525428 A JP 2016525428A JP 2016525428 A JP2016525428 A JP 2016525428A JP 6928450 B2 JP6928450 B2 JP 6928450B2
Authority
JP
Japan
Prior art keywords
irl
brain
patent document
receptor
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016525428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523969A (ja
JP2016523969A5 (https=
Inventor
アニール グラティ，
アニール グラティ，
Original Assignee
ミッドウェスタン ユニバーシティ
ミッドウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミッドウェスタン ユニバーシティ, ミッドウェスタン ユニバーシティ filed Critical ミッドウェスタン ユニバーシティ
Publication of JP2016523969A publication Critical patent/JP2016523969A/ja
Publication of JP2016523969A5 publication Critical patent/JP2016523969A5/ja
Priority to JP2020179020A priority Critical patent/JP7385924B2/ja
Application granted granted Critical
Publication of JP6928450B2 publication Critical patent/JP6928450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016525428A 2013-07-08 2014-07-08 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 Active JP6928450B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020179020A JP7385924B2 (ja) 2013-07-08 2020-10-26 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843702P 2013-07-08 2013-07-08
US61/843,702 2013-07-08
US201361902935P 2013-11-12 2013-11-12
US61/902,935 2013-11-12
PCT/US2014/045748 WO2015006324A2 (en) 2013-07-08 2014-07-08 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020179020A Division JP7385924B2 (ja) 2013-07-08 2020-10-26 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物

Publications (3)

Publication Number Publication Date
JP2016523969A JP2016523969A (ja) 2016-08-12
JP2016523969A5 JP2016523969A5 (https=) 2017-08-10
JP6928450B2 true JP6928450B2 (ja) 2021-09-01

Family

ID=52280704

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016525428A Active JP6928450B2 (ja) 2013-07-08 2014-07-08 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
JP2020179020A Active JP7385924B2 (ja) 2013-07-08 2020-10-26 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020179020A Active JP7385924B2 (ja) 2013-07-08 2020-10-26 エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物

Country Status (10)

Country Link
US (2) US10561704B2 (https=)
EP (1) EP3019242B1 (https=)
JP (2) JP6928450B2 (https=)
CN (2) CN105682741A (https=)
AU (1) AU2014287427B2 (https=)
BR (1) BR112016000431A8 (https=)
CA (2) CA3171883C (https=)
ES (1) ES2825101T3 (https=)
PL (1) PL3019242T3 (https=)
WO (1) WO2015006324A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
PL3813942T3 (pl) * 2018-05-03 2024-07-22 Midwestern University Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
KR20260005957A (ko) * 2023-04-26 2026-01-12 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩티드 및 이의 응용
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
DE60335743D1 (de) * 2002-11-20 2011-02-24 Neuronova Ab Verbindungen und verfahren zur erhöhung der neurogenese
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
EP1996222A2 (en) 2006-03-23 2008-12-03 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
CN101888851B (zh) * 2007-08-21 2013-11-20 美国中西部大学 使用内皮缩血管肽b受体激动剂治疗中风或脑血管意外的组合物
CN101374259B (zh) * 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
KR101418941B1 (ko) * 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물

Also Published As

Publication number Publication date
JP2021020945A (ja) 2021-02-18
EP3019242A2 (en) 2016-05-18
WO2015006324A3 (en) 2015-11-05
ES2825101T3 (es) 2021-05-14
CA3171883C (en) 2024-03-05
US20200353031A1 (en) 2020-11-12
WO2015006324A8 (en) 2016-01-28
US20160151450A1 (en) 2016-06-02
CN113384701A (zh) 2021-09-14
AU2014287427A1 (en) 2016-02-11
WO2015006324A2 (en) 2015-01-15
US10561704B2 (en) 2020-02-18
EP3019242B1 (en) 2020-08-19
CA2917325A1 (en) 2015-01-15
JP7385924B2 (ja) 2023-11-24
JP2016523969A (ja) 2016-08-12
PL3019242T3 (pl) 2021-02-08
CN105682741A (zh) 2016-06-15
CA3171883A1 (en) 2015-01-15
CA2917325C (en) 2023-09-05
BR112016000431A8 (pt) 2018-01-23
EP3019242A4 (en) 2017-01-25
AU2014287427B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
Rajmohan et al. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons
Ballesteros-Alvarez et al. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease
Hammerschmidt et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice
Faivre et al. Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
Kitazawa et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model
Leung et al. Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats
Wu et al. Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease
Zeng et al. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity
Koller et al. Tau-mediated dysregulation of neuroplasticity and glial plasticity
US11844767B2 (en) Composition and methods for stimulating clearance of amyloid-beta protein
Leung et al. Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
JP2025142087A (ja) アルファ－シヌクレインの調節因子
US20210038589A1 (en) Uses, compositions and methods
JP7097444B2 (ja) 脳小血管病の治療用医薬の製造における化合物の使用
Abyadeh et al. Amyloid-beta and tau protein beyond Alzheimer’s
Yang et al. Investigating the impact of dysregulated brain metabolism on synaptic and cognitive outcomes
Kirylo Estrogen replacement therapy to reduce neurodegeneration and socio-cognitive deficits in a female Sprague Dawley rat model of early-onset Alzheimer’s disease
Royea Unraveling the Role of the Renin Angiotensin System in Cerebrovascular and Memory Deficits in Alzheimer's Disease
Modi Protection of memory and learning by cinnamon
Zaciragic et al. Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders
Shao See Into The Future Understanding the acute and progressive pathophysiology of oxygen induced retinopathy for potential therapeutic development
Brothers Neuroinflammation induces time-dependant behavioral, cellular and molecular changes that resemble characteristics of Alzheimer’s and Parkinson’s diseases and can be modulated by caffeine administration
Vegh et al. Investigation into Efficacy and Mechanisms of Neuroprotection of Ashwagandha Root Extract and Water-Soluble CoenzymeQ10 in a Transgenic Mouse Model of Alzheimer’s Disease. Nutrients 2025, 17, 2701

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190122

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190520

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20190604

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190604

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200728

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201110

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201201

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210615

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210727

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210806

R150 Certificate of patent or registration of utility model

Ref document number: 6928450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250